Tisagenlecleucel (tisa-cel, formerly CTL019), an anti-CD19 CAR T-cell therapy with a 4-1BB costimulatory domain, was more extensively tested and later approved for ALL in children and young adults (ELIANA trial [29]). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.